Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Peng L, Liang J, Wang H, Song X, Rashid A, Gomez HF, Corley LJ, Abbruzzese JL, Fleming JB, Evans DB, Wang H.

Clin Cancer Res. 2010 Jul 15;16(14):3734-42. doi: 10.1158/1078-0432.CCR-09-3411. Epub 2010 Jul 13.

2.

High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Liang JJ, Zhu S, Bruggeman R, Zaino RJ, Evans DB, Fleming JB, Gomez HF, Zander DS, Wang H.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2598-604. doi: 10.1158/1055-9965.EPI-10-0405. Epub 2010 Aug 23.

3.

Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, Abbruzzese JL, Evans DB, Wang H.

Clin Cancer Res. 2008 Nov 1;14(21):7043-9. doi: 10.1158/1078-0432.CCR-08-0381.

4.

Overexpression of nucleolin and different expression sites both related to the prognosis of gastric cancer.

Qiu W, Zhou F, Zhang Q, Sun X, Shi X, Liang Y, Wang X, Yue L.

APMIS. 2013 Oct;121(10):919-25. doi: 10.1111/apm.12131. Epub 2013 Jun 14.

PMID:
23763304
5.

Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Weng S, Wang H, Chen W, Katz MH, Chatterjee D, Lee JE, Pisters PW, Gomez HF, Abbruzzese JL, Fleming JB, Wang H.

Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1336-43. doi: 10.1158/1055-9965.EPI-12-0223. Epub 2012 Jun 4.

6.

Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma.

Song X, Wang H, Logsdon CD, Rashid A, Fleming JB, Abbruzzese JL, Gomez HF, Evans DB, Wang H.

Cancer. 2011 Feb 15;117(4):734-43. doi: 10.1002/cncr.25483. Epub 2010 Oct 4.

7.

Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases.

Cao D, Zhang Q, Wu LS, Salaria SN, Winter JW, Hruban RH, Goggins MS, Abbruzzese JL, Maitra A, Ho L.

Mod Pathol. 2007 May;20(5):570-8. Epub 2007 Mar 30.

8.

Prognostic significance of nuclear or cytoplasmic nucleolin expression in human non-small cell lung cancer and its relationship with DNA-PKcs.

Xu JY, Lu S, Xu XY, Hu SL, Li B, Li WX, Chang JY.

Tumour Biol. 2016 Aug;37(8):10349-56. doi: 10.1007/s13277-016-4920-6. Epub 2016 Feb 4.

PMID:
26846099
9.

Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma.

Yamamoto S, Tomita Y, Hoshida Y, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K.

Ann Surg Oncol. 2004 Feb;11(2):165-72.

PMID:
14761919
10.

The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy.

Bever KM, Sugar EA, Bigelow E, Sharma R, Laheru D, Wolfgang CL, Jaffee EM, Anders RA, De Jesus-Acosta A, Zheng L.

HPB (Oxford). 2015 Apr;17(4):292-8. doi: 10.1111/hpb.12334. Epub 2014 Sep 23.

11.

Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.

Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H.

J Hematol Oncol. 2012 Apr 4;5:15. doi: 10.1186/1756-8722-5-15.

12.

Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.

Xia JT, Wang H, Liang LJ, Peng BG, Wu ZF, Chen LZ, Xue L, Li Z, Li W.

Pancreas. 2012 May;41(4):629-35. doi: 10.1097/MPA.0b013e31823bcef2.

PMID:
22249132
13.

Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma.

Foo WC, Rashid A, Wang H, Katz MH, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, Fleming JB, Wang H.

Hum Pathol. 2013 Jun;44(6):1024-30. doi: 10.1016/j.humpath.2012.09.001. Epub 2012 Dec 20.

14.

EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.

Park SJ, Gu MJ, Lee DS, Yun SS, Kim HJ, Choi JH.

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8298-304. eCollection 2015.

15.

Low expression of nucleus accumbens-associated protein 1 predicts poor prognosis for patients with pancreatic ductal adenocarcinoma.

Nishi T, Maruyama R, Urano T, Nakayama N, Kawabata Y, Yano S, Yoshida M, Nakayama K, Miyazaki K, Takenaga K, Tanaka T, Tajima Y.

Pathol Int. 2012 Dec;62(12):802-10. doi: 10.1111/pin.12020.

PMID:
23252869
16.

HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.

Richards NG, Rittenhouse DW, Freydin B, Cozzitorto JA, Grenda D, Rui H, Gonye G, Kennedy EP, Yeo CJ, Brody JR, Witkiewicz AK.

Ann Surg. 2010 Sep;252(3):499-505; discussion 505-6. doi: 10.1097/SLA.0b013e3181f1fd44.

PMID:
20739850
17.

Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance?

Gebauer F, Kemper M, Sauter G, Prehm P, Schumacher U.

PLoS One. 2017 Jun 5;12(6):e0178703. doi: 10.1371/journal.pone.0178703. eCollection 2017.

18.

Differential mucin phenotypes and their significance in a variation of colorectal carcinoma.

Imai Y, Yamagishi H, Fukuda K, Ono Y, Inoue T, Ueda Y.

World J Gastroenterol. 2013 Jul 7;19(25):3957-68. doi: 10.3748/wjg.v19.i25.3957.

19.

Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma.

Cates JM, Byrd RH, Fohn LE, Tatsas AD, Washington MK, Black CC.

Pancreas. 2009 Jan;38(1):e1-6. doi: 10.1097/MPA.0b013e3181878b7f.

20.

Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.

Piao J, Liu S, Xu Y, Wang C, Lin Z, Qin Y, Liu S.

Exp Mol Pathol. 2015 Feb;98(1):1-6. doi: 10.1016/j.yexmp.2014.11.003. Epub 2014 Nov 5.

PMID:
25445504

Supplemental Content

Support Center